Premature Atherosclerosis in Systemic Lupus Erythematosus
Section snippets
Systemic lupus erythematosus and coronary artery disease: epidemiologic evidence of association
The first cases suggesting an association between SLE and atherosclerotic CAD were reported in the 1960s [2]. In 1976, Urowitz et al [3] described the bimodal pattern of mortality in SLE based on a case series of 11 deaths among 81 patients followed for 5 years at the University of Toronto Rheumatic Disease Unit. Six of the 11 deaths occurred within the first year after diagnosis in patients who had active disease. In four of the six early deaths, a major septic episode contributed to the
Atherosclerosis in noncoronary vessels: a link with coronary artery disease
AS often affects multiple vessel territories in the same patient. Studies have shown that in patients who have diabetes, a classic risk factor for cardiovascular disease, AS in one vessel territory is a risk factor for presence of AS in other vascular territories [11]. Similarly in patients who do not have diabetes, coronary and cerebral arterial disease often coexist with small studies showing up to 20% to 40% prevalence of silent cardiac ischemia in patients who have a history of stroke,
Subclinical atherosclerosis in systemic lupus erythematosus: prevalence and methods of detection
Many patients who have SLE have subclinical AS with no history of MI or stroke. Detection of subclinical AS is not only important in determining the true prevalence of AS in SLE but also provides a window of opportunity for prevention of subsequent ischemic events. In addition, studying the natural history of subclinical disease may provide valuable insight in to means of attenuating risk and enhancing protective factors for adverse future outcomes.
Factors associated with coronary artery disease in systemic lupus erythematosus: interplay between disease, therapy, and conventional cardiovascular risk factors
Defining risk factors associated with premature AS in SLE is fundamental to understanding the pathogenesis of this complication and prevention of ischemic events and cardiovascular mortality in this disease. The large population-based Framingham Study has identified major risk factors for the development of CAD in the general population [36], [37]. These risk factors include hypertension, hypercholesterolemia (> 5.2 mmol/L), low HDL cholesterol (< 0.9 mmol/L), current smoking, diabetes
Novel risk factors for coronary artery disease in systemic lupus erythematosus
There has been much interest in identification of novel risk factors for CAD. Although many such risk factors have been proposed, most have yet to be linked conclusively to CAD in patients who have SLE, or indeed, in the general population.
Role of antiphospholipid antibodies in atherogenesis in systemic lupus erythematosus
Antiphospholipid antibodies (aPLs) are the hallmark of the antiphospholipid syndrome, which is characterized by arterial and venous thrombosis. Up to 47% of patients who have SLE have elevated levels of aPL [66]. High levels of aPLs have been linked to MI in young patients in several prospective studies [67], [68], [69] and shown to be an independent risk factor for MI and cardiac death in middle-aged men [70], [71]. Studies have also shown a link between anti-B2GPI antibodies and ischemic
New tools for cardiovascular risk profiling and their use in systemic lupus erythematosus
With advances in the understanding of vessel physiology and applications of ultrasound technology, there has been a trend away from invasive angiographic assessment of flow-limiting coronary lesions toward measuring earlier changes in structural and functional aspects of vessels potentially amenable to reversal with intervention.
Continuum of vascular disease in systemic lupus erythematosus and the concept of nonocclusive coronary artery disease
In the study by Sella et al [31], only 8 of 21 patients with myocardial perfusion defects and no history of CAD had coronary plaques identified on angiography. The investigators have also noted similar findings where of 21 patients with perfusion defects on MPS (10 of whom were symptomatic for CAD), 14 (67.0%) had no occlusive lesions on angiography [91]. In a descriptive study of 35 patients who had SLE and underwent coronary angiography in the course of routine clinical care in a 25-year
An approach to screening patients who had systemic lupus erythematosus for risk of future ischemic events
As discussed, several conventional cardiovascular risk factors have been shown to be associated with the development of clinical CAD in prospective cohort studies. All patients who have SLE should, therefore, be regularly screened for the presence of cardiovascular risk factors. The first tier of screening must include obtaining history in relation to smoking and measurement of body weight, blood pressure, serum cholesterol (including HDL and LDL), triglycerides, and blood glucose, as well as
Modifying risk factors for coronary artery disease in systemic lupus erythematosus
In the Toronto Risk Factor Study, a prospective cohort-control study of 250 women who had SLE without clinical CAD, compared with 250 age-matched controls, hypertension (RR 2.59, 95% CI 1.79–3.75, P = 0.001), and diabetes (RR 6.00, 95% CI 1.36–26.53, P = 0.0066) were significantly more common among patients who had SLE [44]. SLE patients also had higher levels of VLDL cholesterol and total triglycerides, and higher levels of homocysteine. Premature menopause, sedentary lifestyle, and an at-risk
Summary
The association between SLE and premature CAD has been well established. Longitudinal cohort studies have estimated the prevalence of CAD in SLE to be at least 10%. However, despite variations in the technique used, the prevalence of subclinical CAD is close to 35%, indicating that the burden of this complication is in fact greater than may at first appear. Clinicians must therefore have a low threshold for cardiac evaluation in patients who have SLE, including premenopausal women who present
References (108)
- et al.
The bimodal mortality pattern of systemic lupus erythematosus
Am J Med
(1976) - et al.
Ischemic heart disease in systemic lupus erythematosus in the young patient: report of six cases
Am J Cardiol
(1982) - et al.
Risk factors for coronary artery disease in patients with systemic lupus erythematosus
Am J Med
(1992) - et al.
Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome
Am J Cardiol
(2001) - et al.
The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients
Am J Med
(1975) - et al.
Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus
Am J Med
(1984) - et al.
Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study
J Am Coll Cardiol
(1993) - et al.
Prediction of coronary events with electron beam computed tomography
J Am Coll Cardiol
(2000) - et al.
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
Lancet
(1996) - et al.
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
Lancet
(1998)
Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis
Clin Immunol Immunopathol
Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations
Am J Med
Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study
Am J Med
Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis?
Immunobiology
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force
J Am Coll Cardiol
Close relation of endothelial function in the human coronary and peripheral circulations
J Am Coll Cardiol
Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease
Am J Med
Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women
J Am Coll Cardiol
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death
J Rheumatol
Fatal myocardial infarction in lupus erythematosus. Report of a case of a young female patient
Vasc Dis
Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy
Acta Pathol Jpn
Mortality in systemic lupus erythematosus: the bimodal pattern revisited
Q J Med
Morbidity in systemic lupus erythematosus
J Rheumatol
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study
Am J Epidemiol
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus
Arthritis Rheum
The risk of stroke following coronary revascularization—a population-based long-term follow-up study
Scand Cardiovasc J
Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association
Stroke
Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors [abstract 1570]
Arthritis Rheum
Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study
Rheumatology (Oxford)
Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus
Arthritis Rheum
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
N Engl J Med
Peripheral vascular disease in patients with systemic lupus erythematosus
Ann Rheum Dis
Lower-limb vascularization in diabetic patients. Assessment by thallium-201 scanning coupled with exercise myocardial scintigraphy
Diabetes Care
Usefulness of thallium-201 muscle scan to investigate perfusion reserve in the lower limbs of patients with systemic lupus erythematosus
Rheumatol Int
High prevalence of asymptomatically poor muscle perfusion of lower extremities measured in systemic lupus erythematosus patients with abnormal myocardial perfusion
Rheumatol Int
Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study
Stroke
Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus
Arthritis Rheum
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus
Ann Rheum Dis
Ultrasonic biopsy—a non-invasive screening technique to evaluate the cardiovascular risk and to follow up the progression and the regression of arteriosclerosis
Vasa
Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study
J Rheumatol
Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities
J Rheumatol
Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy
Arthritis Rheum
Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis
Arch Intern Med
Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography
Circulation
Premature coronary-artery atherosclerosis in systemic lupus erythematosus
N Engl J Med
Coronary risk prediction in adults (the Framingham Heart Study)
Am J Cardiol
Prediction of coronary heart disease using risk factor categories
Circulation
Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus
J Rheumatol
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus
Arthritis Rheum
Epidemiology of systemic lupus erythematosus
Cited by (81)
The brain in SLE: Mechanisms and detection of injury and therapeutic strategies
2021, Lahita’s Systemic Lupus ErythematosusAcute Myocardial Infarction Outcomes in Systemic Lupus Erythematosus (from the Nationwide Inpatient Sample)
2019, American Journal of CardiologyCitation Excerpt :Autoimmune vascular damage may contribute to accelerated atherosclerosis, coronary vasculitis, and arterial thrombosis. Therefore, the etiology of acute coronary syndromes may vary from nonocclusive coronary artery or thrombotic occlusion with angiographically normal or mildly diseased coronary vasculature to vascular wall inflammation in young patients and coronary atherosclerosis in older patients.21 Based on the results of our analysis, AMI in SLE did not necessarily translate into a higher in-hospital mortality rate.
A rare case of acute myocardial infarction with a non-specific symptom in a young female with systemic lupus erythematosus
2017, Journal of Cardiology CasesCitation Excerpt :On the other hand, however, both lesions may coexist in the same coronary arteries, as suggested in an autopsy study by Takayanagi et al., who reported that atherosclerotic lesions and inflammatory lesions coexisted in the coronary arteries [10]. Although coronary angiography may be useful for distinguishing between these conditions, it does not allow imaging of the coronary microvasculature where the pathophysiology may lie [11]. Thus, it may be difficult to clearly differentiate between them, and we assume that both lesions may coexist in many cases of CHD in patients with SLE.
The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model
2015, International Journal for ParasitologyCardiac involvement in adult patients with autoimmune inflammatory rheumatic diseases
2023, Cardiologia Hungarica
This work was supported by the Geoff Carr Lupus Fellowship from the Ontario Lupus Association.